Humanigen, Inc. (NASDAQ:HGEN – Get Rating) shares rose 3.7% during trading on Tuesday . The stock traded as high as $0.17 and last traded at $0.17. Approximately 1,205,421 shares were traded during trading, a decline of 59% from the average daily volume of 2,964,703 shares. The stock had previously closed at $0.16.

Analyst Upgrades and Downgrades

HGEN has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on Humanigen in a research note on Wednesday, January 11th. They set a "neutral" rating for the company. Credit Suisse Group reissued an "underperform" rating and set a $0.50 target price on shares of Humanigen in a research note on Monday, April 3rd.

Humanigen Trading Up 3.7 %

The firm has a market capitalization of $19.65 million, a PE ratio of -0.11 and a beta of -0.84. The business has a 50 day moving average price of $0.15 and a 200-day moving average price of $0.15.

Institutional Investors Weigh In On Humanigen

A number of large investors have recently bought and sold shares of the stock. Virtu Financial LLC boosted its holdings in shares of Humanigen by 225.9% during the fourth quarter. Virtu Financial LLC now owns 301,792 shares of the company's stock worth $36,000 after purchasing an additional 209,195 shares during the last quarter. Renaissance Technologies LLC raised its position in Humanigen by 72.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,491,771 shares of the company's stock valued at $179,000 after purchasing an additional 626,071 shares during the period. UBS Group AG raised its position in Humanigen by 293.0% in the fourth quarter. UBS Group AG now owns 206,151 shares of the company's stock valued at $25,000 after purchasing an additional 153,695 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Humanigen by 2,848.4% in the third quarter. Bank of New York Mellon Corp now owns 620,733 shares of the company's stock worth $112,000 after acquiring an additional 599,680 shares in the last quarter. Finally, Telemetry Investments L.L.C. lifted its stake in shares of Humanigen by 584.9% in the third quarter. Telemetry Investments L.L.C. now owns 500,000 shares of the company's stock worth $90,000 after acquiring an additional 427,000 shares in the last quarter. Institutional investors and hedge funds own 6.93% of the company's stock.

About Humanigen

(Get Rating)

Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.

Recommended Stories

• Get a free copy of the StockNews.com research report on Humanigen (HGEN)
• United Parcel Service Delivers A Warning To The Market
• Pulte Homes Is Hosting The Better, More Profitable Open House
• Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
• A Top Is In For McDonald's Corporation Stock
• Strong Demand Makes Cleveland-Cliffs an Undervalued Mid-Cap

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.